Multi‐omic molecular profiling guide’s efficacious treatment selection in refractory metastatic breast cancer: a prospective phase II clinical trial-Reference-Cited by-同舟云学术

Multi‐omic molecular profiling guide’s efficacious treatment selection in refractory metastatic breast cancer: a prospective phase II clinical trial

Published:2021-09-12 Issue:1 Volume:16 Page:104-115
ISSN:1574-7891
Container-title:Molecular Oncology
language:en
Short-container-title:Molecular Oncology

Author:

Pierobon Mariaelena¹^ORCID,Robert Nicholas J.²,Northfelt Donald W.³,Jahanzeb Mohammad⁴,Wong Shukmei⁵,Hodge Kimberly A.¹,Baldelli Elisa¹,Aldrich Jessica⁵,Craig David W.⁵,Liotta Lance A.¹,Avramovic Sanja⁶,Wojtusiak Janusz⁶,Alemi Farrokh⁶,Wulfkuhle Julia D.¹,Bellos Angela¹,Gallagher Rosa I.¹,Arguello David⁷,Conrad Amber⁷,Kemkes Ariane⁸,Loesch David M.⁸,Vocila Linda⁹,Dunetz Bryant¹⁰,Carpten John D.⁵,Petricoin Emanuel F.¹,Anthony Stephen P.¹¹

Affiliation:

1. George Mason University Manassas VA USA

2. US Oncology Network/Virginia Cancer Specialists Fairfax VA USA

3. Mayo Clinic Arizona Scottsdale AZ USA

4. A Division of 21^st Century Oncology Florida Precision Oncology Raton FL USA

5. Translational Genomics Research Institute Phoenix AZ USA

6. Department of Health Administration and Policy George Mason University Fairfax VA USA

7. Caris Life Sciences Phoenix AZ USA

8. Paradigm Diagnostics Phoenix AZ USA

9. Translational Drug Development (TD2) Scottsdale AZ USA

10. The Side‐Out Foundation Fairfax VA USA

11. Evergreen Hematology‐Oncology Spokane WA USA